Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 14/20 | 1.00 |
| ▸ | CTSS | P25774 | 13/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1630655 | 0.83 | CTSS (0.70) | CTSKCTSS | |
| SCHEMBL3125399 | 0.78 | CTSK (0.64) | CTSKCTSSKCNH2XDHCTSL | |
| SCHEMBL3118138 | 0.76 | CTSS (0.61) | CTSKCTSS | |
| SCHEMBL3116353 | 0.76 | CTSS (1.00) | CTSKCTSS | |
| SCHEMBL3115133 | 0.76 | CTSS (0.70) | CTSKCTSS | |
| SCHEMBL3106495 | 0.74 | CTSK (0.59) | CTSKCTSSKCNH2XDHIDO1 | |
| SCHEMBL3110876 | 0.74 | CTSS (1.00) | CTSKCTSS | |
| SCHEMBL30235028 | 0.74 | CTSS (0.58) | CTSKCTSSXDHIDO1 | |
| SCHEMBL1924945 | 0.70 | CTSK (0.54) | CTSKCTSSKCNH2XDHCTSL | |
| SCHEMBL8744699 | 0.70 | CTSS (0.61) | CTSKCTSSKCNH2XDHIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979351-B1 | 6-PHENYL-1H-IMIDAZO[4, 5-C]PYRIDINE-4-CARBONITRILE DERIVATIVES AS CATHEPSIN K AND S INHIBITORS | ORGANON NV (NL) | 2010-04-07 | — | — | EP | disclosed |
| US-7687515-B2 | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives | N.V. ORGANON (NL) | 2010-03-30 | — | — | US | disclosed |
| US-7687515-B2 | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives | N.V. ORGANON (NL) | 2010-03-30 | — | — | US | disclosed |
| US-7687515-B2 | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives | N.V. ORGANON (NL) | 2010-03-30 | — | — | US | disclosed |
| EP-1979351-A1 | 6-PHENYL-1H-IMIDAZO[4, 5-C]PYRIDINE-4-CARBONITRILE DERIVATIVES AS CATHEPSIN K AND S INHIBITORS | N.V. Organon (NL) | 2008-10-15 | — | — | EP | disclosed |
| US-20070179138-A1 | 6-Phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives | N.V. ORGANON (NL) | 2007-08-02 | — | — | US | disclosed |
| US-20070179138-A1 | 6-Phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives | N.V. ORGANON (NL) | 2007-08-02 | — | — | US | disclosed |
| US-20070179138-A1 | 6-Phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives | N.V. ORGANON (NL) | 2007-08-02 | — | — | US | disclosed |
| WO-2007080191-A1 | 6-PHENYL-1H-IMIDAZO[4, 5-C]PYRIDINE-4-CARBONITRILE DERIVATIVES AS CATHEPSIN K AND S INHIBITORS | N.V. ORGANON (NL) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007080191-A1 | 6-PHENYL-1H-IMIDAZO[4, 5-C]PYRIDINE-4-CARBONITRILE DERIVATIVES AS CATHEPSIN K AND S INHIBITORS | N.V. ORGANON (NL) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179138-A1 | 6-Phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives | CTSK, CTSS, CTSZ | CTSK 1/4885CTSS 2/4885KCNH2 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.